Craig Thompson - Merck Independent Director

MRK Stock  USD 131.95  0.20  0.15%   

Director

Dr. Craig B. Thompson, M.D. is Independent Director of the Company. He is President and Chief Executive Officer of Memorial SloanKettering Cancer Center since 2010 since 2008.
Age 64
Tenure 16 years
Address 126 East Lincoln Avenue, Rahway, NJ, United States, 07065
Phone908 740 4000
Webhttps://www.merck.com
Thompson was Professor of Medicine at the University of Pennsylvania School of Medicine from 1999 to 2011 and Director of the Abramson Cancer Center from 2006 to 2010. Fellow, American Academy of Arts and Sciences; Member, Medical Advisory Board of the Howard Hughes Medical Institute and The National Academy of Sciences and its Institute of Medicine.

Merck Management Efficiency

The company has Return on Asset of 0.0264 % which means that on every $100 spent on assets, it made $0.0264 of profit. This is way below average. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Capital Employed is expected to slide to 0.04. The value of Return On Assets is estimated to slide to 0. At this time, Merck's Non Current Liabilities Total is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 10.8 B this year, although the value of Total Current Liabilities will most likely fall to about 13.3 B.
The company has 36.27 B in debt with debt to equity (D/E) ratio of 0.68, which is OK given its current industry classification. Merck Company has a current ratio of 1.43, which is typical for the industry and considered as normal. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Linda HudsonBank Of America
70
Jim WaltonWalmart
65
Kenneth ChenaultInternational Business Machines
66
Steuart WaltonWalmart
38
Monica LozanoBank Of America
64
Robert DenhamChevron Corp
71
David WeinbergThe Coca Cola
69
John PlantAlcoa Corp
61
Howard BuffettThe Coca Cola
60
Sarah FriarWalmart
47
Debra ReedKlagesChevron Corp
63
John StumpfChevron Corp
61
Ursula BurnsExxon Mobil Corp
62
Patricia RussoAlcoa Corp
63
Richard DaleyThe Coca Cola
75
Joseph SwedishInternational Business Machines
69
ron SugarChevron Corp
66
Linda WolfWalmart
66
James UmplebyChevron Corp
60
Thomas HortonWalmart
59
Margaret GeorgiadisMcDonalds
56
Merck Co., Inc. operates as a healthcare company worldwide. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 67000 people. Merck Company (MRK) is traded on New York Stock Exchange in USA. It is located in 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 and employs 70,000 people. Merck is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Merck Company Leadership Team

Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Scot Ebbinghaus, VP Development
Rochelle Lazarus, Independent Director
Michael Rosenblatt, Executive Vice President Chief Medical Officer
Paul Rothman, Independent Director
Mary Coe, Independent Director
Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer
Caroline Litchfield, Chief Financial Officer, Executive Vice President
Mirian GraddickWeir, Executive Vice President - Human Resources
Jannie Oosthuizen, Lead - Human Health U.S.
Jennifer Mauer, VP Communications
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
Gregory Lubiniecki, VP Development
Michael Klobuchar, Executive Vice President Chief Strategy Officer
Patricia Russo, Independent Director
David Williams, Executive Vice President Chief Information Chief Information and Digital Officer
Franklin Clyburn, President, Human Health, Head of Human Health Commercial and Marketing
Lisa LeCointeCephas, Senior Vice President Chief Ethics and Compliance Officer
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
Robert Kidder, Independent Director
Thomas Cech, Independent Director
William Harrison, Lead Independent Director
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
Jim Scholefield, Executive Vice President, Chief Information and Digital Officer
Deepak Khanna, Lead - Human Health International
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Gideon Blumenthal, Vice Affairs
Adam Schechter, President of Global Human Health and Executive VP
Risa LavizzoMourey, Independent Director
Thomas Glocer, Lead Independent Director
Craig Thompson, Independent Director
Cristal Downing, Executive Vice President, Chief Communications, Public Affairs Officer
Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary
Arpa Garay, Lead - Human Health Global Marketing
Dalton III, Principal Finance
Christine Seidman, Independent Director
Wendell Weeks, Independent Director
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer
Kathy Warden, Independent Director
Adele Ambrose, Senior Vice President Chief Communications Officer
Joseph Romanelli, IR Contact Officer
Peter Wendell, Independent Director
John Noseworthy, Independent Director
Leslie Brun, Lead Independent Director
Inge Thulin, Independent Director
Pamela Craig, Independent Director
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller
Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories
Chirfi Guindo, Senior Health
Joerg Koglin, Vice Development
Stephen Mayo, Independent Director
Michael Nally, Executive Vice President, Chief Marketing Officer
Peter Dannenbaum, Vice Relations
Clark Golestani, CIO and Executive VP
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer
Carlos Represas, Independent Director
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer
Frank Clyburn, Executive Vice President, Chief Commercial Officer
Robert JD, President Chairman

Merck Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Merck Stock analysis

When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
CEOs Directory
Screen CEOs from public companies around the world
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Commodity Directory
Find actively traded commodities issued by global exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.453
Dividend Share
2.92
Earnings Share
0.14
Revenue Per Share
23.695
Quarterly Revenue Growth
0.058
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.